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The biological processes that come into play during orthodontic tooth movement (OTM)
have been shown to be influenced by a variety of pharmacological agents. The effects
of such agents are of particular relevance to the clinician as the rate of tooth movement
can be accelerated or reduced as a result. This review aims to provide an overview of
recent insights into drug-mediated effects and the potential use of drugs to influence
the rate of tooth movement during orthodontic treatment. The limitations of current
experimental models and the need for well-designed clinical and pre-clinical studies are
also discussed.
Keywords: orthodontics, orthodontic tooth movement, tooth movement, pharmacology, pharmacological agents
INTRODUCTION
During orthodontic treatment, the application of sustained force on teeth sets in motion processes
that ultimately lead to alveolar bone remodeling. These biochemical processes involve a multitude
of cellular and molecular networks (Ren and Vissink, 2008; Zainal Ariffin et al., 2011; d’Apuzzo
et al., 2013; Patil et al., 2013). Pharmacological agents have the potential to interfere with the
biochemical processes which govern tooth movement during, and stability after, orthodontic
treatment. As a result, the possibility to accelerate/enhance OTM where needed (such as in areas
of space closure) and to halt tooth movement where desired (to provide anchorage or to ensure
positional tooth stability during the initial retention period) has attracted considerable interest in
the field. Already in 1982 Yamasaki et al. showed that local administration of prostaglandins E1 or
E2 accelerated experimental tooth movement in monkeys (Macaca fuscata) (Yamasaki et al., 1982).
In the present article we review reported experimental results on drugs that can modulate
orthodontic tooth movement (OTM) and discuss the potential of pharmacological strategies aimed
at supporting orthodontic interventions.
Molecular Players Involved In Orthodontic Tooth Movement (OTM)
A necessary prerequisite for selecting, designing and testing suitable molecules to influence OTM
is a detailed knowledge of the role of the different cellular and molecular components driving the
biological process of OTM.
To achieve OTM, mechanical forces are applied on teeth. This initially causes fluid movement
within the periodontal ligament (PDL) space and distortion of the PDL components (cells,
extracellular matrix, and nerve terminals), setting into motion the process of release of a multitude
of molecules (neurotransmitters, cytokines, growth factors, arachidonic acid metabolites etc.)
which initiate alveolar bone remodeling (Krishnan and Davidovitch, 2006).
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Orthodontic load strains nerve endings present in the PDL.
These release in response a number of neuropeptides (substance
P, vasoactive intestinal polypeptide, and calcitonin gene-related
peptide-CGRP), which act on capillaries and cause the adhesion
and migration of blood leukocytes into the area of compression
(Krishnan and Davidovitch, 2006). These very active cells release
signaling proteins (cytokines, growth factors) with a direct
effect on cells of the periodontium. In addition, local hypoxia
(unavoidably caused in areas of compression by occlusion of
the PDL vessels) activates hypoxia-inducible transcription factor
(HIF)-1α in endothelial cells and osteoblasts (Dandajena et al.,
2012). This leads to expression of downstream genes including
VEGF (vascular endothelial growth factor) and receptor activator
of NF-kB ligand (RANKL), which mediate the recruitment of
peripheral blood mononuclear cells/osteoclast lineage cells from
PDL capillaries and their conversion/activation into osteoclasts,
respectively.
Furthermore, when cells in the periodontium (fibroblasts,
osteoblasts, endothelial and bone lining cells) are subjected to
mechanical stress they express cytokines, growth factors and
cytokine receptors. Osteoblasts express IL-1b, IL-6, IL-11, TNFa
and their receptors in response to compressive stress. IL-b shows
an autocrine effect and enhances the phenomenon (Koyama
et al., 2008) plus induces osteoblasts to promote osteoclast
activity (through induction of RANKL expression). IL-6 is
involved in osteoclast recruitment and differentiation. TNFa
directly stimulates the differentiation of osteoclast precursors to
osteoclasts in the presence of M-CFS (which is a glycoprotein
produced by fibroblasts and endothelial cells in response to
growth factors and cytokines, such as PDGF, FGF, IL-1, and IL-
6). IL-11 enhances the expression of RANKL, a key molecule
in osteoclast precursor differentiation, in osteoblasts. In areas
of tension, growth factors (e.g., TGF-β) and cytokines (e.g.,
OPG) produced by PDL cells can induce apoptosis of osteoclasts
(Kobayashi et al., 2000) and tip the balance toward bone
formation.
One of the immediate responses of the PDL at sites
of compression is also the rise in the level of matrix
metalloproteinases (MMPs) which are produced by activated
fibroblasts.
MMPs either degrade collagen fibers (MMP-1 and MMP-8)
or eliminate the degraded collagen (MMP-9 and MMP-2) to
allow tooth movement (Lekic and McCulloch, 1996; Cantarella
et al., 2006). The degradation of collagen is thought to enhance
osteoclast activation, osteoclast migration and adhesion to bone.
Another very important class of molecules expressed by
PDL cells under force application (compression or tension)
are the chemokines. These are chemotactic cytokines that have
been recognized as playing key roles in inflammatory processes
but only recently the role of CC inflammatory chemokines in
mechanically-induced bone remodeling is starting to become
clearer (Andrade et al., 2009; Taddei et al., 2012; Lee et al.,
2015). In general, chemokines mediate chemotaxis of leukocytes
and bring about cellular differentiation. In the PDL, interaction
between CCL2 (chemokine ligand 2) and CCR2 (chemokine
receptor 2) have been found to mediate osteoclast precursor
attraction to the sites of orthodontic force application and to
subsequently induce osteoclast terminal differentiation possibly
through their action on RANK and RANKL expression (Taddei
et al., 2012). Another chemokine ligand expressed in the
PDL under mechanical loading, CCL3, exerts its effects by
interacting with chemokine receptors 1 and 5 (CCR1 and
CCR5) present on the surface of osteoclasts and osteoblasts.
The effects of chemokines seem to be of different nature
depending on the receptor to which they bind, as the CCL3-
CCR1 interaction leads to the induction of bone resorption by
osteoclast recruitment, differentiation/activation (Taddei et al.,
2013), while the interaction of chemokines with CCR5 inhibits
bone resorption by increasing the production of signals (such
as IL-10 and OPG) inhibitory to osteoclast activation (Andrade
et al., 2009).
Prostaglandins and leukotrienes are additional players in the
process of tooth remodeling. These molecules are produced
by enzymatic processing of arachidonic acid, a component
derived from phospholipids of cell tissue membranes. They
are locally produced hormones with low serum concentration
(Smith, 1989). Prostaglandin production can be induced by
mechanical stress or by growth factors, hormones and cytokines
(such as IL-1, IL-6, and TNF-a) present at the sites of tooth
movement. Prostaglandins mediate events such as vasodilation,
inflammatory cell recruitment and also act directly on PDL cells.
Prostaglandin E2 (PGE2) is the most widely researched
PG with respect to OTM. PGE2 is produced mainly by
PDL fibroblasts and osteoblasts (Kanzaki et al., 2002) by the
action of the inducible enzyme COX-2 (cyclooxygenase 2), and
subsequently by a specific synthase enzyme (PGE synthase).
The newly formed PGE2 has different effects depending on
the type of transmembrane receptor to which it binds. PGE2
can drive RANKL expression in osteoblasts (by binding to the
EP2 or EP4 receptors), which subsequently leads to osteoclast
activation (Mayahara et al., 2012), or drive bone mineralization
by osteoblasts when binding to the EP1 receptor (Fujieda et al.,
1999). In addition, PGE2 has been shown to aid osteoclast
formation (Collins and Chambers, 1992) or lead to transient
osteoclast inhibition when added to osteoclasts in vitro (Fuller
and Chambers, 1989).
Leukotrienes are also produced through the enzymatic
metabolism of arachidonic acid by 5-lipooxygenase in many
cells including osteoclasts or leucocytes chemoattracted to areas
of inflammation. The two leukotrienes shown to be involved
in tooth movement are LTB4 (leukotriene B4) and LTD4 (a
cysteinyl leukotriene), (Moura et al., 2014). Both leukotrienes
were found to significantly boost the recruitment and terminal
differentiation/activation of osteoclasts through their effect on
cytokine synthesis and in the presence of RANKL.
The induction of osteoclasts is also regulated at various levels
by inhibitor molecules, such as OPG (whose expression is up-
regulated in cells of the periodontium including osteoblasts
under tensile stress possibly through the COX pathway of
PG synthesis), IL-1RA (a receptor antagonist cytokine which
controls the effects of IL-1), IL-12, and IL-10 (which inhibits
the RANK osteoclast signaling pathway and other osteoclast
stimulating processes) under low stress conditions (Park-Min
et al., 2009). In addition, regulatory T cells by direct contact to
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osteoclasts and through secretion of cytokines such as IL-10 and
TGF-β also play a key role in suppressing osteoclastic activity
(Zaiss et al., 2007). Balanced osteoclast activity is necessary to
prevent uncontrollable osteolysis and control bone metabolism
during OTM.
An outline of the main cellular and molecular components of
OTM is shown in Figure 1.
The Search for Pharmacological Agents to
Control Orthodontic Tooth Movement
In the last decades an increasing number of pharmacological
agents have been explored aiming at the identification of suitable
pharmacological means of accelerating or inhibiting OTM.
Experimental evidence is mainly based on in vitro and animal
studies, and a limited number of case-control clinical studies. In
the next sections, current knowledge on pharmacological agents
that may accelerate or decelerate tooth movement is discussed
(Table 1).
Pharmacological Acceleration of OTM
Arachidonic Acid Metabolites
Among the arachidonic acid metabolites, PGE2 is by far the most
widely tested substance in terms of its capacity to modify OTM.
Evidence, mainly derived from animal studies, points toward a
positive effect of PGE2 with respect to enhancing bone resorption
and accelerating tooth movement (Yamasaki et al., 1982, 1984;
Leiker et al., 1995; Kale et al., 2004). The few available clinical
studies are of low quality and involve repeated injections of PGE2
and follow-up times of a maximum of 60 days (Camacho and
Velásquez Cujar, 2014). The mode of application of PGE2 is a
major limitation as it involves repeated injection (due its short
half-life) in combination with an anaesthetic solution to alleviate
the hyperalgesia caused by injection of PGE2. Potential adverse
effects (e.g., root resorption) linked to long-term administration
of PGE2, as required in the context of orthodontic treatment, are
possible given its mode of action but have not been evaluated so
far.
Specific synthases are involved in the pathway of the synthesis
of each type of prostaglandins (e.g., PGE and PGD synthases) and
many of them have been cloned and could provide drug targets
for the regulation of the synthesis of specific prostaglandins, such
as PGE2 in the case of OTM (Forsberg et al., 2000). In addition,
it is possible that other PGs such as PGI2 may be involved in
bone resorption providing further targets for drugs (Wang et al.,
1999). Another obvious group of drug targets are the identified
receptors of specific prostaglandins (such as the receptors EP1,
EP2, or EP4 of prostaglandin PGE2) and the design of selective
agonists can provide pharmacological methods of modifying
OTM through these receptors.
Intravenous immunoglobulin (IVIg) preparations are
polyspecific and polyclonal immunoglobulin therapeutic
preparations used as a replacement therapy in immunodeficient
patients (Grader-Beck et al., 2011; Schneider et al., 2015). These
IVIg preparations were shown to induce COX-2 mediated PGE2
synthesis and cytokine production (Trinath et al., 2013; von
Gunten et al., 2013; Djoumerska-Alexieva et al., 2015). It is
possible that local administration of these IVIg preparations
could be used to modulate bone modeling through PEG2
induction and bypass some of the limitations of PEG2 injections.
Hormones (Parathyroid Hormone,
1,25-Dihydroxycholecalciferol, Relaxin)
Parathyroid hormone (PTH) exerts its effects directly on
osteoblasts and indirectly on osteoclasts through binding
to the PTH type 1 receptor on osteoblasts, leading to
expression of insulin-like growth factor-1 (IGF-1), which
promotes osteoblastogenesis and osteoblast survival, and of
RANKL, which promotes osteoclast activation. PTH is also likely
interacting with bone lining cells promoting early osteogenesis
(Dobnig and Turner, 1995; Esbrit and Alcaraz, 2013)
Recombinant PTH is clinically used for the treatment of
osteoporosis and has been shown to mediate bone anabolic
or catabolic effects depending on the circumstances of
administration (Esbrit and Alcaraz, 2013). Intermittent exposure
to PTH seems to increase bone formation, while continuous
and long-term exposure (longer than 1–2 years) enhances bone
resorption. Studies on the effects of PTH on tooth movement
point toward a role of intermittent treatment with PTH in
facilitating bone remodeling/turnover and therefore accelerating
tooth movement. This is possibly occurring by PTH enhancing
both osteoblast and subsequently also osteoclast activity (Li
et al., 2013). To date there no long-term studies employing local
PTH delivery that discriminate between effects of PTH on tooth
movement when different protocols are used (short-term vs.
long-term administration and intermittent or continuous mode
of administration). Some short-term animal studies indicate
that a system of slow, continuous release of PTH in areas of
compression is able to accelerate OTM (Soma et al., 1999, 2000).
1,25-dihydroxycholecalciferol or calcitriol is the most active
metabolite of vitamin D and has predominantly anabolic,
but also catabolic effects on bone. Furthermore, vitamin D
also modulates the transcription of genes in immune cells
(von Gunten et al., 2013). Calcitriol seems to enhance bone
remodeling in a similar way to PTH by enhancing osteoblastic
proliferation and function (Reichel et al., 1989), while both PTH
and 1,25-dihydroxycholecalciferol have been shown to stimulate
PG production in osteoblasts further implicating them in the
process of OTM (Pilbeam et al., 1989; Klein-Nulend et al., 1991).
Some evidence from animal experiments exists on the effect
of local application of calcitriol on tooth movement (Takano-
Yamamoto et al., 1992; Kale et al., 2004; Kawakami and Takano-
Yamamoto, 2004). During the short experimental time of the
available studies there is some evidence that calcitriol enhances
the processes of alveolar bone resorption and formation (bone
remodeling) leading to acceleration of tooth movement during
force application (Takano-Yamamoto et al., 1992; Kale et al.,
2004), and also enhances bone formation and remodeling after
OTM (Kawakami and Takano-Yamamoto, 2004). A clinical study
testing the effects of systemic application of calcitriol indicated
that it may produce some enhancement in tooth movement
(Blanco et al., 2001).
Relaxin is a peptide hormone with strong effects on collagen
turn-over. In vitro studies have suggested that relaxin may
have a direct effect on the PDL by means of decreasing the
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FIGURE 1 | An outline of the cellular and molecular mechanism behind the process of OTM. Potential pharmacological agents that could be used to affect
OTM and their site of action are indicated.
expression and release of collagen type I, increasing expression
of certain MMPs and decreasing the expression of inhibitors
of metalloproteinases (TIMPs), (Henneman et al., 2008; Takano
et al., 2008, 2009) in PDL cells. Despite increased interest in the
potential of relaxin tomodulate OTM, effects on toothmovement
and tooth stabilization could to date not be confirmed, neither
clinically (McGorray et al., 2012) nor in animal experiments
(Stewart et al., 2005; Madan et al., 2007).
Pharmacological Deceleration of OTM
OPG and RANKL
The potential use of osteoprotegerin (OPG) to inhibit tooth
movement and enhance stability, stems from the known
physiological role that OPG plays within the PDL in regulating
the bone resorbing activity of osteoclasts. OPG is produced by
osteoblasts and is a decoy receptor for RANKL which prevents
the interaction of RANKL present on osteoblasts’ surface with its
receptor RANK on osteoclasts. In the absence of RANKL-RANK
interactions, the activation, terminal differentiation and survival
of osteoclasts are negatively affected. Changes in the ratio of
RANKL/OPG in the PDL can fine-tune alveolar bone resorption.
A number of groups attempted to influence tooth movement
in animal models by locally altering the concentration of either
OPG or RANKL aiming to enhance or decrease the resorptive
action of osteoclasts (Kanzaki et al., 2004, 2006; Dunn et al., 2007;
Zhao et al., 2012). A local gene transfer method to increase the
expression of either OPG or RANKL in periodontal tissues was
used in some studies, in which acceleration of tooth movement
by gene transfer of RANKL and inhibition by gene transfer of
OPG were observed. For the short experimental time periods
used, gene transfer is reported to have caused no alterations in
bonemetabolism in bones distant from the site of injection (Zhao
et al., 2012).
Of note is that Denosumab, a humanized monoclonal
antibody against RANKL, has recently been added to the list of
pharmacological agents used to combat osteoporosis but has not
been evaluated with respect to OTM (Bekker et al., 2004; Boyce
and Xing, 2008).
Bisphosphonates
Bisphosphonates exert a strong inhibitory effect on bone
resorption and are successfully used for the treatment of
osteoporosis. With respect to the possible effects of different
bisphosphonates on toothmovement, in vitro studies have shown
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TABLE 1 | Agents with proposed potential of accelerating or decelerating
orthodontic tooth movement (OTM).
Acceleration of OTM Deceleration of OTM
Arachidonic acid metabolites N-acetylcysteine
Cytokines Bisphosphonates (Clodronate, Aledronate)
1,25-dihydroxycholecalciferol Chemically modified tetracyclines (CMTs)
RANKL CetylPyridinium Chloride (CPC)
Parathyroid hormone Integrin inhibitors
Relaxin Osteoprotegerin
Compiled from recent original work and reviews, as discussed in this article. RANKL,
receptor activator of NF-kB ligand.
that both aledronate (Kim et al., 2012) and clodronate (Liu
et al., 2006) inhibit the stress-induced up-regulation of key
components crucial for mediating tooth movement. Clodronate
was shown to reproducibly inhibit the stress-induced expression
of COX-2, PGE2, and RANKL in cultured human PDL-derived
cells in a concentration-dependent manner (Liu et al., 2006).
This action of clodronate is likely to indirectly prevent osteoclast
formation and allow osteoclast apoptosis. Kim et al. used
chitosan scaffolds loaded with aledronate to investigate possible
effects of this bisphosphonate on osteoblasts and on RANKL-
induced differentiation of osteoclasts (Kim et al., 2012). They
observed concentration-dependent positive effects of aledronate
on the proliferation, differentiation and activity of osteoblasts,
and a potent inhibitory effect on osteoclast differentiation. An
interesting aspect of this study was that chitosan aledronate
releasing scaffolds seem to ensure a sustained release of
aledronate for a period of 4 weeks, suggesting that this system
might provide a feasible delivery vehicle for long-term treatment.
Cytokine and Chemokine Receptor Antagonists
Cytokines are released following mechanical stimulation of cells
in the PDL. Their effects on initiating tooth movement are
mediated through binding to cytokine receptors on target cells.
Decreasing the amount of the unbound cytokines could be a
possible strategy of reducing toothmovement. This approach was
taken in two studies examining the effects of systemic application
of soluble cytokine receptors on tooth movement and root
resorption in rodents (Zhang et al., 2003; Jäger et al., 2005). The
authors concluded that the administration of soluble receptors to
IL-1 and TNF-a, or their combination, led to reduction in OTM
in all receptor-treated groups by approximately 50% (Jäger et al.,
2005). Furthermore, the number and activity of osteoclasts and
odontoclasts were reduced.
Another potential approach is to increase the production
of osteoclast inhibitory cytokines such as IL-10 and TGF-β. A
potential compound with its origins in the chinese medicine is
triptolide, which upregulates the production of these cytokines
by regulatory T cells (Xu et al., 2016). A water soluble
compound of triptolide, minnelide, has recently become available
and is currently used in clinical trials to combat pancreatic
cancer.
A potential pharmacological approach to decrease bone
resorption and tooth movement is through the use of specific
chemokine receptor antagonists, such as Met-RANTES, a
modified methionylated CCL5 molecule, which binds to both
CCR1 and CCR5 receptors and blocks the physiological signaling
pathway that leads to bone resorption (Proudfoot et al., 1996;
Taddei et al., 2012). Such an intervention could be used to
enhance anchorage by preventing the movement of teeth under
mechanical loading.
Antibiotics/Antiseptics
Chemically modified tetracyclines (CMTs) are derivatives of the
tetracycline groups of antibiotics that lack antimicrobial activity
and the adverse effects associated with the conventional
tetracyclines. Their ability to inhibit MMPs and pro-
inflammatory cytokines and their apoptotic effects on osteoclasts
initially rendered them attractive therapeutic agents for the
management of chronic periodontitis. The CMTs have been
shown to modify the COX-2 enzyme leading to inhibition of
PGE2 production (Patel et al., 1999) and represent also potent
inhibitors of MMPs (Marcial et al., 2012). These properties
make CMTs a potentially useful pharmacological agent to inhibit
tooth movement in order to control anchorage or enhance tooth
stability after orthodontic treatment. Initial animal studies (Bildt
et al., 2007) showed that oral administration of CMT-3 (now
known as COL-3) reduced the rate of tooth movement in rats
in a concentration-dependent manner. The exact mechanism of
action remains to be elucidated.
Another antibacterial agent, enoxacin, offers an attractive
approach for controlling the resorptive activity of osteoclasts.
For the resorption of bone mineral, the presence of proton
pumps in the ruﬄed borders of osteoclasts is crucial. To this end,
osteoclasts have the unique ability to produce increasing amounts
of vacuolar (V) ATPases (proton pumps) upon their activation.
These V-ATPases are transported through interaction with
microfilaments within the cytoplasm to the plasma membrane-
a unique ability limited to clast cells, thus making the targeting
of this process a highly specific means for modulation of tooth
movement. Enoxacin was first identified by crystal structure-
based virtual screening as one of the potential molecules which
could block the binding site of V-ATPase to actin (Ostrov
et al., 2009). Such interference would in principle prevent
transportation of the proton pumps to the ruﬄed border of
the osteoclast. In vitro studies confirmed the predicted effect
(Ostrov et al., 2009) and animal studies showed that a modified
version of enoxasin (bis-enoxacin) with enhanced binding to
bone selectively inhibited osteoclasts resulting in inhibition of
tooth movement in rats after 28 days (Toro et al., 2013).
There is also some evidence from in vitro experiments that the
well-known antiseptic Cetyl Pyridinium Chloride (CPC) inhibits
RANKL-induced osteoclast formation from bone marrow-
derived macrophages possibly by supressing a key event in the
RANKL induced intracellular signaling pathway or by interfering
with M-CFS signaling (Zheng et al., 2013). To our knowledge
potential inhibitory effects of CPC on OTM have not been tested
to date. Its already approved use in dental medicine due to its
antiseptic properties renders CPC an attractive agent to test for
potential beneficial effects on tooth stability after orthodontic
treatment.
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Antioxidants
The theoretical possibility that antioxidants may interfere with
tooth movement derives from observations that the cellular
concentration of reactive oxygen species (ROS) increases under
conditions of hypoxia and mechanical stress in PDL fibroblasts
and that hypoxia has been shown to lead to the expression of key
genes involved in the recruitment and activation of osteoclasts
(Janssen-Heininger et al., 2000; Dandajena et al., 2012). Altered
ROS levels also influence the characteristics of immune cells
(Wehrli et al., 2014).
The effects of antioxidants (either resveratrol or N-
acetylcysteine) were tested in a split mouth design in rats
(Chae et al., 2011). The authors reported a significant decrease
in tooth movement compared to the control sites following local
injection of N-acetylcysteine but not resveratrol.
Integrin Inhibitors
Integrins are a group of transmembrane glycoproteins, which
form heterodimeric units on the membrane of PDL clast cells,
such as osteoclasts and odontoclasts (Talic et al., 2004). One of
their functions is the adhesion of the differentiated clast cells onto
specific proteins on bone (e.g., osteopontin) and dentine enabling
them to become polarized and start the bone resorption process,
but members of the group mediate other functions such as clast
cell migration, cell differentiation and survival.
Integrin molecules adhere to proteins containing RGD
(standing for the amino acids arginine, glycine and aspartate)
epitopes. Such proteins include osteopontin and bone
sialoprotein (Miyauchi et al., 1991). This property has been
exploited and a number of studies have used RGD-containing
peptides as antagonists to prevent integrin function. With
respect to tooth movement, based on results from animal
models it appears that there is the potential for RGD peptides
to inhibit tooth movement (Dolce et al., 2003) and also root
resorption (Talic et al., 2006). There is, however, indication
from the experimental results that a more detailed knowledge
of the function of the different integrin molecules is crucial, as
generalized inhibition of integrin function at PDL sites may have
a multitude of undesirable effects.
Another potential means of exploring the role of RGD
peptides and inhibiting tooth movement is through the use of
MMP inhibitor molecules to reduce the production of RGD
peptides byMMPs in areas of compression (Holliday et al., 2003).
This animal study used a general (rather than specific) MMP
inhibitor, Ilomastat, locally delivered and demonstrated some
reduction in bone resorptive osteoclast activity.
Limitations of the Available Studies
Toothmovement is a complex process controlled by the nature of
the mechanical stimuli, by a multitude of signaling pathways and
influenced by the individual’s genetic make-up (Zainal Ariffin
et al., 2011). Naturally, the huge majority of available in vivo
experimental evidence derives from animal studies. These have
major limitations which include: (1) the inherently different
biology in animals which prevents complete inference of the
effects and the side effects of the pharmacological agents in
humans, (2) the inability to calculate from animal experiments
suitable dosages for clinical testing, as systemic application of the
drug is often used in these models and may not result in effective
or comparable (species difference) drug concentrations at the site
of orthodontic intervention, (3) the generally small sample sizes
used and different ages of animals used, which makes reliable
conclusions even in the animal studies impossible to be reached,
(4) the lack of longer-term animal studies, which would enable
examination of the effects of an agents on tooth movement over
a time period and also allow observation of side-effects.
When clinical human studies are conducted, there are obvious
problems related to ethical and practical issues: (1) recruitment
of sufficient patient numbers, (2) evaluation of the effect of
individual variation, (3) need for initial dose-response studies
including measurements to assess the levels of the therapeutic
agent at the sites of interest and measurements of the tissue-level
outcomes.
The huge majority of the above mentioned studies have
employed a systemic administration or local injection of
the pharmacological agents. There is multitude of problems
associated with these approaches. A systemic administration
does not ensure a constant delivery of an ideal dose of the
agent in the PDL. As it is not clear how circulating values
correspond to the gingival dose and how they fluctuate in time,
mainly due to degradation of the agent, in many cases a dose
tested in the experimental set-up could have been insufficient to
obtain the desired biologic effect. A more important problem is
the potential of systemic administration to provoke undesirable
systemic effects, especially when pharmacological agents lacking
specificity are used. Themere evaluation of side effects is doubtful
in the current experimental protocols as either the test periods are
too short or the experimental protocol has not included specific
methods to evaluate such effects.
Local injection of a pharmacological agent or local gene
transfer also come with significant problems. For an intervention
to be clinically useful, it must be characterized by practicality
in its application (in terms of cost and time) and minimal
discomfort for the patient. Daily or even frequent invasive
procedures are a major prohibiting factors for clinical
application. In addition, during tooth movement different
biological processes take place at distinct sites of the PDL. Bone
resorption and bone formation occur simultaneously at different
areas of the PDL (areas of compression. vs. areas of tension). The
proteoglycan component of the extracellular matrix of the PDL,
a hydrated gel, allows the diffusion of free small molecules (such
as drugs, hormones) within the pdl and presents a big challenge
to the effort of achieving targeted therapeutic interventions
at specific sites (compressions vs. tension). Most of the drugs
used can and will influence both processes and can furthermore
influence other physiological cellular functions. The use of
integrin inhibitors is a good example of that.
FUTURE DIRECTIONS
The Need for the Design of Specific
Pharmacological Agents
Targeting key processes in the bone remodeling mechanism
without other undesirable local side effects precludes a detailed
knowledge of the cellular events involved. The selection of
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appropriate targets for the drugs and the design of novel
drugs or suitable analogs of naturally occurring molecules with
high specificity, is key for clinically successful strategies. The
pharmacological agents also need to demonstrate high potency
and efficacy in order to achieve clinically significant differences.
The cost implications of the process of designing, testing and
eventually obtaining approval for the clinical application of a
potential therapeutic agents need to be carefully considered and
kept to the minimum to decrease the eventual cost to the patient.
A very useful approach as demonstrated by the processes that led
to the identification of enoxacin, is to screen already known and
approved molecules for clinical applications.
Development of Suitable Vehicles of Drug
Delivery and Mode of Administration
Suitable drug delivery materials need to be developed to provide
the appropriate mode of release of pharmacological agents in
their active form, that is, at the desired rate and amount for a long
period of time (reflecting the duration of orthodontic treatment
or retention time). Sustained and low grade prostagladin release
through a suitable delivery system could, for example, be used to
induce and sustain further endogenous PG production (through
a known amplifyingmechanism). This can be used to prolong the
effects of short periods of stress in OTM.
It is also important that the drug carriers do not have a
tendency to spread into a larger area from the application
site or that are induced only at areas of bone remodeling
(such as matrix-bound inducible molecules). An ideal
vehicle for drug delivery must be non-toxic/biocompatible
(Démoulins et al., 2013), and be biodegradable (so that
no second procedure for its removal is needed) with a
suitable half-life and ideally allowing controlled release
and alternating delivery of various pharmacological agents,
when desired. A convenient method of application (minimal
surgical intervention) and reasonable cost are also required
to make its clinical application attractive. Materials that
have so far been experimentally used for the purpose of
delivering drugs to influence tooth movement include
the polymer ELVAX (a non-biodegradable polymer) and
methylcellulose (in injectable, gel formulation). However,
their use was only tested during experimental periods of short
duration.
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